Detalles de la búsqueda
1.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ann Hematol;
102(7): 1773-1787, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37171597
2.
Correction to: REMIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (polaBR), CART therapies, and lenalidomide/rituximab (R2) based on realworld data in patients with relapsed/refractory diffuse large Bcell lymphoma.
Ann Hematol;
102(9): 2643-2644, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432417
3.
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Mult Scler;
23(2): 253-265, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27207449
4.
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Mult Scler;
21(1): 57-66, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24990854
5.
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Clin Cancer Res;
28(18): 4003-4017, 2022 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35674661
6.
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Clin Cancer Res;
27(22): 6124-6134, 2021 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34433649
7.
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
Clin Ther;
37(7): 1402-1419.e5, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25999183
8.
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Curr Med Res Opin;
30(4): 613-27, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24195574
9.
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
Expert Opin Pharmacother;
14(1): 123-36, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23256518
10.
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
Expert Opin Pharmacother;
14(15): 2145-56, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23971970
11.
Ethanol influences on native T-type calcium current in thalamic sleep circuitry.
J Pharmacol Exp Ther;
307(1): 197-204, 2003 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-12893844
Resultados
1 -
11
de 11
1
Próxima >
>>